Berger Montague Announces Class Action for Ultragenyx Pharmaceutical Investors Before April Deadline

Investment Alert: Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc.

Berger Montague, a well-known national plaintiffs’ law firm located in Philadelphia, is leading a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), representing investors who purchased shares during a specific two-year span from August 3, 2023, to December 26, 2025. The firm advises interested investors to reach out before the approaching deadline on April 6, 2026.

Background of the Lawsuit

Ultragenyx Pharmaceutical Inc., based in Novato, California, specializes in developing treatments for rare diseases. However, the lawsuit claims that the company made misleading statements regarding key studies—specifically the Phase 3 ORBIT and COSMIC programs—that examined the effectiveness of setrusumab as a potential treatment for Osteogenesis Imperfecta.

The crux of the issue lies in the allegation that Ultragenyx did not accurately represent the outcomes of these clinical trials. On December 29, 2025, the company faced public scrutiny when it announced that neither of the studies had achieved their primary endpoints, a revelation that led to a staggering decline in the company's share price—over 42% in just a single trading day.

Importance of Acting Quickly

Investors who bought shares during the specified class period are encouraged to engage with Berger Montague to determine their eligibility and discuss potential actions they can take. The firm aims to appoint a lead plaintiff to represent the interests of all affected shareholders. Involvement in this legal action might provide a channel for investors to seek compensation for losses incurred due to the alleged misrepresentations by the company.

To understand your rights as an investor, it is crucial to reach out to Berger Montague as soon as possible. You can contact Andrew Abramowitz at [email protected] or dial (215) 875-3015. Alternatively, Caitlin Adorni is available at [email protected] or (267) 764-4865 to provide assistance.

Berger Montague’s Proven Track Record

Founded more than 55 years ago, Berger Montague stands as a prominent player in complex civil litigation, particularly in class action lawsuits and mass torts. The firm's history brims with notable successes, having recovered over $50 billion for its clients across various domains. Not only does the firm hold expertise in securities law, but its practice areas also cover antitrust, consumer protection, environmental law, and employment law.

The experience and formidable reputation of Berger Montague can be a critical factor in navigating the complexities of this class action suit. Their commitment to holding corporations accountable is reflected in their extensive history of precedent-setting cases.

Conclusion

As the deadline for potential claims approaches, the urgency for investors in Ultragenyx Pharmaceutical Inc. cannot be overstated. With the stakes high following the recent revelations about the company's trial results, taking prompt action is essential for those affected. For guidance, reach out to Berger Montague today and ensure your rights as an investor are protected in this ongoing legal matter.